NAD+
500MG
A synthetic single-chain peptide supplied as lyophilised material for controlled, in-vitro laboratory research into GIP, GLP-1, and glucagon receptor activity.
In stock | ≥99% catalog purity
Description
Product specification
Analytical Profile
Catalog data is presented for material identification and laboratory planning. Batch-specific documentation governs the supplied vial.
| RESEARCH NAME | NAD+ · Nicotinamide Adenine Dinucleotide |
| FORMAT | Lyophilised powder · 500 mg vial |
| MOLECULAR FORMULA | C21H27N7O14P2 |
| MOLECULAR MASS | 663.4 g/mol |
| CAS REGISTRY | 53-84-9 |
| ANALYTICAL IDENTITY | HPLC + LC–MS |
| CATALOG CONDITION | Sealed · dry · light-protected · −20°C |
PROTOCOL LITERACY
Reconstitution Sequence
This source-derived sequence assumes a 10 mg vial and a final reference volume of 1.0 mL. The supplied product documentation remains the controlling instruction.
01
02
Peptide solutions aiding tissue repair, recovery, inflammation, and peak performance.
03
Formulations supporting cellular health, resilience, aging, and long-term performance.
04
Peptide solutions for skin renewal, collagen, youthful vitality, and rejuvenation.
05
Peptide solutions for skin renewal, collagen, youthful vitality, and rejuvenation.
UNRECONSTITUTED MATERIAL
-20°C
Keep frozen, dry, sealed, and protected from direct light. Minimise moisture exposure because NAD+ powder is hygroscopic.
After reconstitution
2-8°C
Handling principle
ONE THAW
Avoid repeated freeze–thaw cycles. The prepared solution should remain clear and colourless; discard it if cloudiness, discolouration, or precipitate develops.
PROTOCOL LITERACY
NAD+ DOSAGE CHART
A designed reference covering concentration, weekly schedule models, reconstitution, supply planning, storage, mechanism, study observations, and administration context. It is educational material—not an individualized regimen.
VIAL CONTENT
1.0 MG
+
REFERENCE DILUENT
1.0 MG
=
STOCK CONCENTRATION
1.0 MG/ML
U-100 SCALE
1 Unit = 0.01 ml 100 mcg
01
GRADUAL 8MG MODEL
02
12 MG TRIAL CONTEXT
EDUCATIONAL REFERENCE
GRADUAL DAILY MODEL
| STUDY INTERVAL | STAGE | WEEKLY DOSE | U-100 REFERENCE | SOLUTION VOLUME |
|---|---|---|---|---|
01
WEEKS 1 | INITIATION | 50 MG | 60 UNITS | 0.30 ML |
02
WEEKS 2 | ESCALATION 01 | 75 MG | 45 UNITS | 0.45 ML |
03
WEEKS 3-8 | INITIATION | 6 MG | 100 UNITS | 0.60 ML |
04
WEEKS 9–12 | UPPER REFERENCE | 100 MG | 60 UNITS | 0.80 ML |
05
WEEKS 13–16 | UPPER REFERENCE | 100 MG | 60 UNITS | 0.80 ML |
01
REFERENCE ASSUMPTIONS
Every unit and volume value shown assumes a 10 mg vial prepared to a total reference volume of 1.0 mL.
02
MATERIAL BOUNDARY
This table does not provide preparation or administration instructions.
03
PROTOCOL CONTROL
Trial documentation and qualified clinical oversight—not this chart—must govern all dosing decisions.
Related products
-
Melanotan II
View → This product has multiple variants. The options may be chosen on the product page -
GLUTATHIONE
View → This product has multiple variants. The options may be chosen on the product page -
GLOW
View → This product has multiple variants. The options may be chosen on the product page -
Epithalon
View → This product has multiple variants. The options may be chosen on the product page -
CJC (W/O DAC) + IPAMORELIN
View → This product has multiple variants. The options may be chosen on the product page -
GHK-Cu
View → This product has multiple variants. The options may be chosen on the product page
Product Enquiry
Have a question about this product? Send us your enquiry and our team will get back to you shortly.